%0 Journal Article
%T Coformulated Bictegravir/Emtricitabine/Tenofovir Alafenamide for Postexposure Prophylaxis After Sexual Assault: A Retrospective Real-World Study.
%A Teresita de Jesús CL
%A Edgar PB
%A Carlos Ruben NC
%A Marla TR
%A Juan Carlos RA
%A Raúl Adrián CF
%A Andrea GR
%J Open Forum Infect Dis
%V 11
%N 8
%D 2024 Aug
%M 39139581
%F 4.423
%R 10.1093/ofid/ofae436
%X We report the experience of bictegravir/emtricitabine/tenofovir alafenamide for nonoccupational postexposure prophylaxis in sexual assault cases. Between June 2021 and October 2023, 39 individuals completed the 28-day follow-up; 41% experienced some side effects, and 1 person discontinued the drug because of a rash. No individuals seroconverted to HIV during the follow-up period.